Published in Br J Cancer on June 27, 2006
Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer (2010) 2.31
Differential regulation of STAT family members by glycogen synthase kinase-3. J Biol Chem (2008) 1.41
PI3K and STAT3: a new alliance. Cancer Discov (2011) 1.31
Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain. J Neuroinflammation (2009) 1.29
Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal (2013) 1.24
Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells. PLoS One (2009) 1.05
Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models. BMC Med (2012) 1.03
HDL and sphingosine-1-phosphate activate stat3 in prostate cancer DU145 cells via ERK1/2 and S1P receptors, and promote cell migration and invasion. Prostate (2010) 1.00
Critical analysis of the potential for targeting STAT3 in human malignancy. Onco Targets Ther (2013) 0.99
Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion. Prostate (2011) 0.97
Prostasin induces protease-dependent and independent molecular changes in the human prostate carcinoma cell line PC-3. Biochim Biophys Acta (2007) 0.97
Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies. Endocr Rev (2008) 0.92
β3 integrin-EGF receptor cross-talk activates p190RhoGAP in mouse mammary gland epithelial cells. Mol Biol Cell (2011) 0.90
Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists. Cancer Sci (2010) 0.87
Correlated alterations in prostate basal cell layer and basement membrane. Int J Biol Sci (2009) 0.84
Bad seeds produce bad crops: a single stage-process of prostate tumor invasion. Int J Biol Sci (2008) 0.83
Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies. Anticancer Agents Med Chem (2010) 0.79
Genetic Interactions of STAT3 and Anticancer Drug Development. Cancers (Basel) (2014) 0.79
Herbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling. Mediators Inflamm (2014) 0.78
CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3. BMC Cancer (2016) 0.75
Tuberatolide B Suppresses Cancer Progression by Promoting ROS-Mediated Inhibition of STAT3 Signaling. Mar Drugs (2017) 0.75
Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell (1986) 20.08
Stat3 as an oncogene. Cell (1999) 17.39
Cancer statistics, 1999. CA Cancer J Clin (1999) 9.18
STATs in oncogenesis. Oncogene (2000) 8.60
Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol (1979) 6.96
Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res (2003) 6.43
Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer (1978) 4.04
EGF receptor. Int J Biochem Cell Biol (1999) 3.91
Negative regulation of fibroblast motility by Ena/VASP proteins. Cell (2000) 3.89
Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res (2002) 3.25
Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest (1998) 3.01
Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science (1990) 2.92
Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ (1997) 2.63
beta-Actin messenger RNA localization and protein synthesis augment cell motility. J Cell Biol (1997) 2.43
Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res (2000) 2.23
STAT signaling in head and neck cancer. Oncogene (2000) 2.19
Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J Cell Biol (1994) 2.12
Localization of all seven messenger RNAs for the actin-polymerization nucleator Arp2/3 complex in the protrusions of fibroblasts. J Cell Sci (2005) 1.95
Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci (1998) 1.77
STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ (2002) 1.69
Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res (2000) 1.68
Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther (2004) 1.68
Stat3 activation in prostatic carcinomas. Prostate (2002) 1.61
Preassociation of STAT1 with STAT2 and STAT3 in separate signalling complexes prior to cytokine stimulation. J Biol Chem (1996) 1.48
Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene (2006) 1.47
The extracellular matrix of gliomas: modulation of cell function. J Neuropathol Exp Neurol (1999) 1.43
Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res (2005) 1.40
The integrin alpha 6 beta 4 and the biology of carcinoma. Biochem Cell Biol (1996) 1.37
STAT activation by epidermal growth factor (EGF) and amphiregulin. Requirement for the EGF receptor kinase but not for tyrosine phosphorylation sites or JAK1. J Biol Chem (1996) 1.35
Growth factor-induced cell motility in tumor invasion. Acta Oncol (2002) 1.34
In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Clin Exp Metastasis (1995) 1.32
Interactions of human ovarian tumor cells with human mesothelial cells grown on extracellular matrix. An in vitro model system for studying tumor cell adhesion and invasion. Exp Cell Res (1985) 1.32
Tumor invasion as dysregulated cell motility. Semin Cancer Biol (2001) 1.31
Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int J Cancer (2004) 1.28
DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling. Exp Cell Res (2004) 1.28
Stat3 is required for the development of skin cancer. J Clin Invest (2004) 1.26
EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int J Oncol (2001) 1.24
RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate (2004) 1.15
Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer. Urology (2005) 1.09
Growth factor receptors as targets for lung cancer therapy. Semin Thorac Cardiovasc Surg (2004) 0.82
Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines. Cancer Res (2001) 0.80
Effects of epidermal growth factor on invasiveness through the extracellular matrix in high- and low-metastatic clones of RCT sarcoma in vitro. Jpn J Cancer Res (1994) 0.80
Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma. Mod Pathol (1994) 0.79
Dolichol-phosphate-mannose-3 (DPM3)/prostin-1 is a novel phospholipase C-gamma regulated gene negatively associated with prostate tumor invasion. Oncogene (2001) 0.77
Male attractiveness and differential testosterone investment in zebra finch eggs. Science (1999) 5.14
A competency model for general practice: implications for selection, training, and development. Br J Gen Pract (2000) 4.25
Cell adhesion and motility depend on nanoscale RGD clustering. J Cell Sci (2000) 4.13
Localized biphasic changes in phosphatidylinositol-4,5-bisphosphate at sites of phagocytosis. J Cell Biol (2000) 3.63
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
Epidermal growth factor receptor activation of calpain is required for fibroblast motility and occurs via an ERK/MAP kinase signaling pathway. J Biol Chem (2000) 2.37
STAT signaling in head and neck cancer. Oncogene (2000) 2.19
Membrane proximal ERK signaling is required for M-calpain activation downstream of epidermal growth factor receptor signaling. J Biol Chem (2001) 2.16
Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J Cell Biol (1994) 2.12
Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol (1998) 2.11
Epidermal growth factor and membrane trafficking. EGF receptor activation of endocytosis requires Rab5a. J Cell Biol (2000) 2.09
Epidermal growth factor activates m-calpain (calpain II), at least in part, by extracellular signal-regulated kinase-mediated phosphorylation. Mol Cell Biol (2004) 2.08
A placebo-controlled trial of ketotifen (HC 20-511, Sandoz) in allergen induced asthma and comparison with disodium cromoglycate. Clin Allergy (1979) 1.98
Two psychological treatments for hypochondriasis. A randomised controlled trial. Br J Psychiatry (1998) 1.95
A survey of the demographics of blood use. Transfus Med (2007) 1.95
Beliefs about worry and intrusions: the Meta-Cognitions Questionnaire and its correlates. J Anxiety Disord (1997) 1.76
Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br J Cancer (2007) 1.75
Cell movement elicited by epidermal growth factor receptor requires kinase and autophosphorylation but is separable from mitogenesis. J Cell Biol (1994) 1.75
Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol (2001) 1.74
Epidermal growth factor alters fibroblast migration speed and directional persistence reciprocally and in a matrix-dependent manner. J Cell Sci (1998) 1.72
Engineering epidermal growth factor for enhanced mitogenic potency. Nat Biotechnol (1996) 1.68
EGF receptor regulation of cell motility: EGF induces disassembly of focal adhesions independently of the motility-associated PLCgamma signaling pathway. J Cell Sci (1998) 1.68
Expressed sequences from conidial, mycelial, and sexual stages of Neurospora crassa. Fungal Genet Biol (1997) 1.62
Biophysical integration of effects of epidermal growth factor and fibronectin on fibroblast migration. Biophys J (1999) 1.58
EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metastasis (1996) 1.57
Internalized epidermal growth factor receptors participate in the activation of p21(ras) in fibroblasts. J Biol Chem (1999) 1.57
Effect of epidermal growth factor receptor internalization on regulation of the phospholipase C-gamma1 signaling pathway. J Biol Chem (1999) 1.57
IP-10 inhibits epidermal growth factor-induced motility by decreasing epidermal growth factor receptor-mediated calpain activity. J Cell Biol (1999) 1.53
A role for gelsolin in actuating epidermal growth factor receptor-mediated cell motility. J Cell Biol (1996) 1.45
In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum Gene Ther (1996) 1.45
Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole. Clin Cancer Res (2000) 1.40
An unexpectedly rapid decline in the X-ray afterglow emission of long gamma-ray bursts. Nature (2005) 1.39
Profilin-1 is a negative regulator of mammary carcinoma aggressiveness. Br J Cancer (2007) 1.39
Mitogenic signaling from the egf receptor is attenuated by a phospholipase C-gamma/protein kinase C feedback mechanism. Mol Biol Cell (1996) 1.35
STAT activation by epidermal growth factor (EGF) and amphiregulin. Requirement for the EGF receptor kinase but not for tyrosine phosphorylation sites or JAK1. J Biol Chem (1996) 1.35
Fatty acid-induced insulin resistance in adipocytes. Endocrinology (1997) 1.35
In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Clin Exp Metastasis (1995) 1.32
PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells. Oncogene (2009) 1.32
Tumor invasion as dysregulated cell motility. Semin Cancer Biol (2001) 1.31
"Subclinical" pacemaker syndrome: a randomised study of symptom free patients with ventricular demand (VVI) pacemakers upgraded to dual chamber devices. Br Heart J (1992) 1.30
Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene (2010) 1.30
Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol (2012) 1.27
Localization of epidermal growth factor receptor in hepatocyte nuclei. Hepatology (1991) 1.27
Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer (2006) 1.25
A role for phospholipase C-gamma-mediated signaling in tumor cell invasion. Clin Cancer Res (1999) 1.25
Comparison of BD Vacutainer SST Plus Tubes with BD SST II Plus Tubes for common analytes. Clin Chim Acta (2001) 1.22
Brief cognitive therapy for panic disorder: a randomized controlled trial. J Consult Clin Psychol (1999) 1.22
Mathematical modeling of epidermal growth factor receptor signaling through the phospholipase C pathway: mechanistic insights and predictions for molecular interventions. Biotechnol Bioeng (2000) 1.21
Two large virion envelope glycoproteins mediate Epstein-Barr virus binding to receptor-positive cells. J Virol (1982) 1.21
A negative feedback loop attenuates EGF-induced morphological changes. J Cell Biol (1991) 1.18
Kinetic and spectroscopic evidence for three actomyosin:ADP states in smooth muscle. J Biol Chem (2000) 1.18
Reactions of police officers to body-handling after a major disaster. A before-and-after comparison. Br J Psychiatry (1991) 1.17
Phosphatidylinositol-4-phosphate 5-kinase-1beta is essential for epidermal growth factor receptor-mediated endocytosis. J Biol Chem (2001) 1.14
Receptors for the complement C3d component and the Epstein-Barr virus are quantitatively coexpressed on a series of B-cell lines and their derived somatic cell hybrids. Cell Immunol (1982) 1.13
Prevalence of tendinitis and related disorders of the upper extremity in a manufacturing workforce. J Rheumatol (1990) 1.11
Insulin-like and insulin-inhibitory effects of monoclonal antibodies for different epitopes on the human insulin receptor. Biochem J (1987) 1.09
Gene therapy for the treatment of oral squamous cell carcinoma. J Dent Res (2003) 1.08
Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst (1998) 1.08
Uveitis and arthritis induced by systemic injection of streptococcal cell walls. Invest Ophthalmol Vis Sci (1986) 1.08
The role of bacterial vaginosis in infection after major gynecologic surgery. Infect Dis Obstet Gynecol (1999) 1.04
Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death. J Immunol (2001) 1.04
Receptor-mediated effects on ligand availability influence relative mitogenic potencies of epidermal growth factor and transforming growth factor alpha. J Cell Physiol (1996) 1.04
EGF receptor signaling in prostate morphogenesis and tumorigenesis. Histol Histopathol (1999) 1.02
Ligand-induced internalization and increased cell calcium are mediated via distinct structural elements in the carboxyl terminus of the epidermal growth factor receptor. J Biol Chem (1991) 1.02
Aging fibroblasts present reduced epidermal growth factor (EGF) responsiveness due to preferential loss of EGF receptors. J Biol Chem (2000) 1.02
Endoscopic sphenopalatine artery ligation is an effective method of treatment for posterior epistaxis. Am J Rhinol (1999) 1.00
The Thought Control Questionnaire--psychometric properties in a clinical sample, and relationships with PTSD and depression. Psychol Med (1999) 1.00
Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline. Br J Cancer (2005) 1.00
Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum (2000) 1.00
Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. Ann Oncol (2010) 1.00
Methadone-maintained former heroin addicts, including those who are anti-HIV-1 seropositive, comply with and respond to hepatitis B vaccination. Addiction (1999) 0.99
PLC gamma contributes to metastasis of in situ-occurring mammary and prostate tumors. Oncogene (2006) 0.99
Psychiatric comorbidity in methadone maintained patients. J Addict Dis (1998) 0.99
An experimental investigation of the role of safety-seeking behaviours in the maintenance of panic disorder with agoraphobia. Behav Res Ther (1999) 0.98
Cognitive factors in predisposition to auditory and visual hallucinations. Br J Clin Psychol (2000) 0.98
Proliferative response of fibroblasts expressing internalization-deficient epidermal growth factor (EGF) receptors is altered via differential EGF depletion effect. Biotechnol Prog (1994) 0.98
Enhanced tumorigenesis of NR6 cells which express non-down-regulating epidermal growth factor receptors. Cancer Res (1991) 0.97
Gamma-ray bursts: huge explosion in the early Universe. Nature (2006) 0.96
Transcriptional suppression of matrix metalloproteinase-2 gene expression in human astroglioma cells by TNF-alpha and IFN-gamma. J Immunol (1998) 0.93
Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis. Eur Respir J (2006) 0.92
Epidermal growth factor (EGF) receptor kinase-independent signaling by EGF. J Biol Chem (2001) 0.92
Bcl-2 but not Bax expression is associated with apoptosis in normal and transformed squamous epithelium. Clin Cancer Res (1998) 0.91
Time-dependent absorption of therapeutic drugs by the gel of the Greiner Vacuette blood collection tube. Ther Drug Monit (2000) 0.90
Comparative mitogenic potencies of EGF and TGF alpha and their dependence on receptor-limitation versus ligand-limitation. Med Biol Eng Comput (1998) 0.90
Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg (2001) 0.89
The prediction of parasuicide repetition in a high-risk group. Br J Clin Psychol (1999) 0.89
Molecular inhibition of phospholipase cgamma signaling abrogates DU-145 prostate tumor cell invasion. Clin Cancer Res (1997) 0.89
The Epstein-Barr virus receptor is distinct from the C3 receptor. J Gen Virol (1983) 0.88
Increased nitric oxide production in the respiratory tract in asymptomatic pacific islanders: an association with skin prick reactivity to house dust mite. J Allergy Clin Immunol (2000) 0.87
Epidermal growth factor induces CD44 gene expression through a novel regulatory element in mouse fibroblasts. J Biol Chem (1997) 0.86
The detection of Epstein-Barr virus receptors utilizing radiolabelled virus. J Gen Virol (1981) 0.86
The nuclear accumulation of a variant epidermal growth factor receptor (EGFR) lacking the transmembrane domain requires coexpression of a full-length EGFR. Mol Cell Biol Res Commun (2000) 0.86
Sickle cell acute chest syndrome associated with parvovirus B19 infection: case series and review. Am J Hematol (1996) 0.85
A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling. J Biol Chem (1999) 0.85
Gefitinib potentiates myeloid cell differentiation by ATRA. Leukemia (2008) 0.84
Significantly improved oral uptake of amikacin in FVB mice in the presence of CRL-1605 copolymer. Life Sci (1999) 0.84
Role of cholecystokinin as a regulator of solid and liquid gastric emptying in humans. Am J Physiol (1996) 0.84
Effects of attention training on hypochondriasis: a brief case series. Psychol Med (1998) 0.84
The eating disorder belief questionnaire: preliminary development. Behav Res Ther (1997) 0.84
Effect of elevated concentration of alkaline phosphatase on cardiac troponin I assays. J Clin Lab Anal (2001) 0.84